Loading...
XLON
AGY
Market cap511mUSD
Jul 14, Last price  
8.00GBP
1D
-3.03%
1Q
40.35%
Jan 2017
-61.68%
IPO
-89.26%
Name

Allergy Therapeutics PLC

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
690.80
EPS
—
Div Yield, %
—
Shrs. gr., 5y
20.81%
Rev. gr., 5y
-5.62%
Revenues
55m
-7.36%
20,606,00023,558,00025,742,00031,022,00037,757,00040,750,00041,552,00041,280,00039,279,00041,955,00043,230,00048,509,00064,138,00068,346,00073,717,00078,204,00084,331,00072,768,00059,587,00055,199,000
Net income
-40m
L-6.63%
-2,191,000-6,173,000-23,256,000-20,297,000-11,764,000586,000-2,662,000823,000536,000741,000108,000-13,072,000-2,481,000-7,533,0003,467,0007,058,0002,886,000-13,776,000-43,071,000-40,216,000
CFO
-32m
L+3.95%
-57,000-8,103,000-18,877,000-19,322,000-440,0001,702,000-2,027,0002,880,0002,432,0002,173,0003,123,000-11,839,000178,000-3,802,0005,600,00012,276,0008,516,000-14,111,000-30,916,000-32,138,000

Profile

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
URL
https://www.allergytherapeutics.com/
IPO date
Oct 11, 2004
Employees
622
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
55,199
-7.36%
59,587
-18.11%
Cost of revenue
90,743
95,901
Unusual Expense (Income)
NOPBT
(35,544)
(36,314)
NOPBT Margin
Operating Taxes
1,050
449
Tax Rate
NOPAT
(36,594)
(36,763)
Net income
(40,216)
-6.63%
(43,071)
212.65%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,417
6,489
BB yield
-1.23%
-42.44%
Debt
Debt current
2,116
1,803
Long-term debt
36,760
34,186
Deferred revenue
7,747
Other long-term liabilities
11,701
11,498
Net debt
25,961
21,144
Cash flow
Cash from operating activities
(32,138)
(30,916)
CAPEX
(3,401)
(4,669)
Cash from investing activities
(1,199)
(4,669)
Cash from financing activities
31,431
29,913
FCF
(37,329)
(32,588)
Balance
Cash
12,915
14,845
Long term investments
Excess cash
10,155
11,866
Stockholders' equity
(192,840)
(116,964)
Invested Capital
239,238
162,074
ROIC
ROCE
EV
Common stock shares outstanding
3,743,332
1,456,288
Price
0.05
399.05%
0.01
-94.94%
Market cap
196,151
1,182.78%
15,291
-94.72%
EV
222,112
36,435
EBITDA
(31,225)
(32,090)
EV/EBITDA
Interest
4,107
2,158
Interest/NOPBT